Healthcare Of Ontario Pension Plan Trust Fund Sage Therapeutics, Inc. Transaction History

Healthcare Of Ontario Pension Plan Trust Fund

$29 Billion
Q1 2024

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Mar 21, 2024	BUY	$17.1 - $22.26 $3.14 Million - $4.09 Million	183,607 Added 1049.18%	201,107 $4.36 Million
Q3 2023 Nov 13, 2023	BUY	$16.75 - $48.98 $293,125 - $857,150	17,500 New	17,500 $360,000
Q1 2023 May 12, 2023	SELL	$37.27 - $46.57 $1.14 Million - $1.42 Million	-30,500 Reduced 54.95%	25,000 $1.05 Million
Q4 2022 Feb 13, 2023	BUY	$32.2 - $43.61 $805,000 - $1.09 Million	25,000 Added 81.97%	55,500 $2.12 Million
Q3 2022 Nov 14, 2022	BUY	$32.28 - $43.27 $56,812 - $76,155	1,760 Added 6.12%	30,500 $1.19 Million

Q2 2022 Aug 11, 2022	SELL	$27.52 - $37.99 $538,263 - $743,046	-19,559 Reduced 40.5%	28,740 $928,000
Q1 2022 May 12, 2022	BUY	$30.71 - $45.71 $1.48 Million - $2.21 Million	48,299 New	48,299 $1.6 Million
Q3 2021 Nov 10, 2021	SELL	$40.26 - $57.37 $21,217 - $30,233	-527 Closed	0 $0
Q2 2021 Aug 12, 2021	SELL	$54.88 - $79.29 $25,299 - $36,552	-461 Reduced 46.66%	527 $30,000
Q1 2021 May 13, 2021	BUY	$70.65 - $96.76 $69,802 - $95,598	988 New	988 $74,000

Others Institutions Holding SAGE

# of Institutions

222

Shares Held

52.7M

Call Options Held

207K

Put Options Held

191K

Vanguard Group Inc Valley Forge, PA

5.75M
Shares

$62 Million
0.0% of portfolio
Rtw Investments, LP New York, NY

5.48M
Shares

$59.1 Million
1.65% of portfolio
Black Rock Inc. New York, NY

4.89M
Shares

$52.7 Million
0.0% of portfolio
Wellington Management Group LLP Boston, MA

4.75M
Shares

$51.2 Million
0.02% of portfolio
State Street Corp Boston, MA

4.49M
Shares

$48.5 Million
0.0% of portfolio

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $641M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Healthcare Of Ontario Pension Plan Trust Fund, based on Form 13F filings with the SEC.

News

Stay updated on Healthcare Of Ontario Pension Plan Trust Fund with notifications on news.

Account